Frederick Financial Consultants LLC Invests $311,000 in Johnson & Johnson (NYSE:JNJ)

Frederick Financial Consultants LLC purchased a new position in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,151 shares of the company’s stock, valued at approximately $311,000.

Several other hedge funds also recently made changes to their positions in the business. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $949,000. Horan Securities Inc. raised its stake in shares of Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its position in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after purchasing an additional 1,271 shares during the period. Lord Abbett & CO. LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $69,859,000. Finally, KPP Advisory Services LLC raised its stake in shares of Johnson & Johnson by 4.7% in the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after purchasing an additional 515 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.3 %

Shares of NYSE JNJ opened at $157.42 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $159.47 and a two-hundred day moving average price of $155.06.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.30%. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Wells Fargo & Company reduced their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $171.72.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.